- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pharma Mar SAU (PHMR)
Pharma Mar SAU stock price live, this page displays BME PHMR stock exchange data. View the PHMR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Pharma Mar SAU real time stock price chart below.
What Is the Pharma Mar SAU Stock Price Today?
The Pharma Mar SAU stock price today is 80.150.
What Is the Stock Symbol for Pharma Mar SAU?
The stock symbol for Pharma Mar SAU is "PHMR."
What Stock Exchange Does Pharma Mar SAU Trade On?
Pharma Mar SAU is listed and trades on the Madrid stock exchange.
Is Pharma Mar SAU a Good Stock to Buy?
Determining whether Pharma Mar SAU—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHMR quote. (ISIN: ES0169501022)
What Is the Pharma Mar SAU Stock Price Today?
The Pharma Mar SAU stock price today is 80.150.
What Is the Stock Symbol for Pharma Mar SAU?
The stock symbol for Pharma Mar SAU is "PHMR."
What Stock Exchange Does Pharma Mar SAU Trade On?
Pharma Mar SAU is listed and trades on the Madrid stock exchange.
Is Pharma Mar SAU a Good Stock to Buy?
Determining whether Pharma Mar SAU—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHMR quote. (ISIN: ES0169501022)
80.150
+1.100(+1.39%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
78.800
80.500
52 wk Range
64.000
105.200
PHMR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
78.80080.500
52 wk Range
64.000105.200
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
PHMR Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
104.889
Upside
+30.87%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
7 Buy
2 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 104.889
(+30.87% Upside)
Earnings
Latest Release
Apr 23, 2026
EPS / Forecast
0.09 / 0.28
Revenue / Forecast
42.9M / 40.9M
Compare PHMR to Peers and Sector
Metrics to compare | PHMR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHMRPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | 11.0x | −0.4x | |
PEG Ratio | 0.00 | 0.26 | 0.00 | |
Price/Book | 0.0x | 2.0x | 2.6x | |
Price / LTM Sales | 0.0x | 4.0x | 3.0x | |
Upside (Analyst Target) | 0.0% | 37.0% | 49.1% | |
Fair Value Upside | Unlock | 8.1% | 6.1% | Unlock |
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to treat small lung cancer cells; and Aplidin, that is extracted from the ascidian Aplidium albicans to treat patients with multiple myeloma. It also develops LAGOON, which is in Phase III clinical trial for the treatment of small cell lung cancer; SaLuDo, which is in Phase III trial to treat patients with metastatic leiomyosarcoma; as well as PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; and SYL1801 that is in phase II clinical trials for treating and preventing choroidal neovascularization, such as age-related macular degeneration (AMD) and diabetic retinopathy. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Pharma Mar (PHMR) Stock Price Today?
The Pharma Mar stock price today is 80.150 EUR.
What Stock Exchange Does Pharma Mar Trade On?
Pharma Mar is listed and trades on the Madrid Stock Exchange.
What Is the Stock Symbol for Pharma Mar?
The stock symbol for Pharma Mar is "PHMR."
What Is the Pharma Mar Market Cap?
As of today, Pharma Mar market cap is 1.390B EUR.
What Is Pharma Mar's Earnings Per Share (TTM)?
The Pharma Mar EPS (TTM) is 4.635.
When Is the Next Pharma Mar Earnings Date?
Pharma Mar will release its next earnings report on Jul 29, 2026.
From a Technical Analysis Perspective, Is PHMR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Pharma Mar Stock Split?
Pharma Mar has split 7 times.
How Many Employees Does Pharma Mar Have?
Pharma Mar has 505 employees.
What is the current trading status of Pharma Mar (PHMR)?
As of Jul 04, 2026, Pharma Mar (PHMR) is trading at a price of 80.150 EUR, with a previous close of 79.050 EUR. The stock has fluctuated within a day range of 78.800 EUR to 80.500 EUR, while its 52-week range spans from 64.000 EUR to 105.200 EUR.
What Is Pharma Mar (PHMR) Price Target According to Analysts?
The average 12-month price target for Pharma Mar is 104.889 EUR, with a high estimate of 125 EUR and a low estimate of 90 EUR. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +30.87% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.